These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy. Croix BS Cytotherapy; 2007; 9(1):1-3. PubMed ID: 17354097 [No Abstract] [Full Text] [Related]
3. Cancer vaccines: toward the next revolution in cancer therapy. Emens LA Int Rev Immunol; 2006; 25(5-6):259-68. PubMed ID: 17169776 [No Abstract] [Full Text] [Related]
4. Cancer vaccines: pessimism in check. Timmerman JM; Levy R Nat Med; 2004 Dec; 10(12):1279; author reply 1279-80. PubMed ID: 15682512 [No Abstract] [Full Text] [Related]
5. The capacity of the immune system to control cancer. Håkansson L Eur J Cancer; 2009 Aug; 45(12):2068-70. PubMed ID: 19608409 [No Abstract] [Full Text] [Related]
9. New frontiers in cell-based immunotherapy of cancer. D'Elios MM; Del Prete G; Amedei A Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938 [TBL] [Abstract][Full Text] [Related]
10. Improving the efficacy of cancer immunotherapy. Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L Eur J Cancer; 2009 May; 45(8):1424-31. PubMed ID: 19167214 [TBL] [Abstract][Full Text] [Related]
11. Technical challenges facing therapeutic cancer vaccines. Ward S; Copier J; Dalgleish A Curr Opin Drug Discov Devel; 2008 Mar; 11(2):168-77. PubMed ID: 18283604 [TBL] [Abstract][Full Text] [Related]
12. New developments in cancer vaccines. Buonaguro L; Aurisicchio L; Buonaguro FM; Ciliberto G Expert Rev Vaccines; 2013 Oct; 12(10):1109-10. PubMed ID: 24124872 [No Abstract] [Full Text] [Related]
13. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011 [TBL] [Abstract][Full Text] [Related]
14. Developing enabling technologies for the success of cancer immunotherapy. Sznol M Curr Opin Investig Drugs; 2004 Dec; 5(12):1239-42. PubMed ID: 15648943 [No Abstract] [Full Text] [Related]
15. Another cancer vaccine, another retreat. Dalzell MD Manag Care; 2013 Feb; 22(2):27-8. PubMed ID: 23451534 [No Abstract] [Full Text] [Related]
16. Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes. Pashov A; Monzavi-Karbassi B; Kieber-Emmons T Vaccine; 2009 May; 27(25-26):3405-15. PubMed ID: 19200843 [TBL] [Abstract][Full Text] [Related]
17. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Fournier P; Schirrmacher V Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773 [TBL] [Abstract][Full Text] [Related]
18. The growing evidence of the role of T-cells in the treatment of solid tumors. Kobayashi A; Pulitanò C; Liddo G; Ohkohchi N Ann Surg Oncol; 2008 Apr; 15(4):1254; author reply 1255. PubMed ID: 18165881 [No Abstract] [Full Text] [Related]
19. Melanoma vaccines: possible progress after years of frustration? Schmidt C J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461 [No Abstract] [Full Text] [Related]
20. Dendritic cells in cancer immunotherapy. Vulink A; Radford KJ; Melief C; Hart DN Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]